Clinical and histologic characteristics of MARs
| . | RAM . |
|---|---|
| No. of rash episodes/patient (n = 14 patients) | |
| 1 | 10 (71) |
| 2 | 4 (29) |
| Mean time to first skin rash, d (n = 14 patients) | 100 [15-336] |
| Rash CTCAE grade (n = 18 rashes) | |
| 1 | 4 (22) |
| 2 | 11 (61) |
| 3 | 2 (11) |
| NA | 1 (6) |
| Clinical presentation (n = 18 rashes) | |
| Papules or plaques | 13 (72) |
| Macules without papules or plaques | 5 (28) |
| Facial edema | 5 (28) |
| Mucosal involvement | 3 (17) |
| Erythroderma | 2 (11) |
| Scaling of the scalp | 2 (11) |
| Pustules | 1 (6) |
| Histopathologic patterns (n = 18 rashes) | |
| Granulomatous | 10 (56) |
| Lichenoid | 9 (50) |
| Psoriasiform/spongiotic | 13 (72) |
| Immunohistochemical analysis (n = 18 rashes) | |
| Intraepidermal CD8+ T cells | 13 (72) |
| CD4+/CD8+ T-cell ratio | 3.5 [0.25-10] |
| PD1+ cells (% lymphoid cells) | 28.9 [0-80] |
| Associated findings (n = 14 patients) | |
| Pruritus | 6 (43) |
| Fever | 2 (14) |
| Elevated serum creatinine | 1 (7) |
| Autoimmune disease (vitiligo, alopecia areata, autoimmune hepatitis, autoimmune thyroiditis) | 5 (36) |
| Management (n = 18 rashes) | |
| Hospital admission | 1 (6) |
| Class III topical steroids | 12 (67) |
| Class IV topical steroids | 4 (22) |
| Antihistamines | 2 (11) |
| No specific treatment | 1 (6) |
| Discontinuation of mogamulizumab (n = 18 rashes) | |
| No | 8 (44) |
| Yes, temporarily | 6 (33) |
| Yes, permanently | 4 (22) |
| Recurrence after rechallenge (n = 6 rechallenges) | 4 (66) |
| . | RAM . |
|---|---|
| No. of rash episodes/patient (n = 14 patients) | |
| 1 | 10 (71) |
| 2 | 4 (29) |
| Mean time to first skin rash, d (n = 14 patients) | 100 [15-336] |
| Rash CTCAE grade (n = 18 rashes) | |
| 1 | 4 (22) |
| 2 | 11 (61) |
| 3 | 2 (11) |
| NA | 1 (6) |
| Clinical presentation (n = 18 rashes) | |
| Papules or plaques | 13 (72) |
| Macules without papules or plaques | 5 (28) |
| Facial edema | 5 (28) |
| Mucosal involvement | 3 (17) |
| Erythroderma | 2 (11) |
| Scaling of the scalp | 2 (11) |
| Pustules | 1 (6) |
| Histopathologic patterns (n = 18 rashes) | |
| Granulomatous | 10 (56) |
| Lichenoid | 9 (50) |
| Psoriasiform/spongiotic | 13 (72) |
| Immunohistochemical analysis (n = 18 rashes) | |
| Intraepidermal CD8+ T cells | 13 (72) |
| CD4+/CD8+ T-cell ratio | 3.5 [0.25-10] |
| PD1+ cells (% lymphoid cells) | 28.9 [0-80] |
| Associated findings (n = 14 patients) | |
| Pruritus | 6 (43) |
| Fever | 2 (14) |
| Elevated serum creatinine | 1 (7) |
| Autoimmune disease (vitiligo, alopecia areata, autoimmune hepatitis, autoimmune thyroiditis) | 5 (36) |
| Management (n = 18 rashes) | |
| Hospital admission | 1 (6) |
| Class III topical steroids | 12 (67) |
| Class IV topical steroids | 4 (22) |
| Antihistamines | 2 (11) |
| No specific treatment | 1 (6) |
| Discontinuation of mogamulizumab (n = 18 rashes) | |
| No | 8 (44) |
| Yes, temporarily | 6 (33) |
| Yes, permanently | 4 (22) |
| Recurrence after rechallenge (n = 6 rechallenges) | 4 (66) |
Data are presented as No. (%) among patients or as mean [range]. CTCAE, Common Terminology Criteria for Adverse Events; NA, not available.